Second-line panitumumab as a triweekly dose for patients with wild-type KRAS exon 2 metastatic colorectal cancer: a single-institution experience

por Daoud, Mohamed A., Aboelnaga, Engy M., Mohamed, Wael M.
Publicado 2016

Clinical outcome and toxicity evaluation of simultaneous integrated boost pelvic IMRT/VMAT at different dose levels combined with androgen deprivation therapy in prostate cancer pa...

por Daoud, Mohamed A, Aboelnaga, Engy M, Alashry, Mohamed S, Fathy, Salwa, Aletreby, Mostafa A
Publicado 2017